Immutep LimitedWed, 1 September 2021, 10:00 pmIn this article:-1.76%Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) --
Last 2ndline PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely dosed, completing recruitment of Stage 2 of Part B
Total of 154 patients out of up to 183 patients (84%) now participating in the expanded trial, with recruitment continuing for the expansion stage of Part A
Further data expected to be reported in calendar year 2021 or early calendar year 2022
SYDNEY, AUSTRALIA – 1 September2021 –Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces that the last patient has been enrolled and safely dosed in Stage 2 of Part B of its Phase II TACTI-002 study (also designated KEYNOTE-798). This completes the recruitment of 2ndline PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patients into the trial.
Immutep expects to report further data from TACTI-002 at a scientific conference in calendar year 2021 or early calendar year 2022.
Patient recruitment is now complete for Parts B and C of TACTI-002 and continues to progress well for the expansion stage of Part A (seeTable 1). A total of 154 patients out of up to 183 are now participating in TACTI-002 at currently 19 clinical sites across Australia, Europe, the UK and US.
Table 1– TACTI-002 Recruitment (as at 24thAugust 2021)
Stage 1 (N)
Actual / TargetStage 2 (N)
Actual / TargetRecruitment
StatusExpansion Stage 3
Actual / Target1 Part A (1st line NSCLC)
17/17
19/19
EXPANDED
43/74
2 Part B (2nd line NSCLC)
23/23
13/13
COMPLETE
3 Part C (2nd line HNSCC)
18/18
21/191
COMPLETE
The data presented for 2nd line PD-1/PD-L1 resistant NSCLC at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting as part of a late breaker poster looked encouraging, especially when compared to alternative treatment options. Based on the data, the DMC confirmed a positive risk-benefit-ratio in this very difficult to treat patient population with confirmed progression (i.e. two consecutive scans) and often low PD-L1 expression levels and recommended the opening of Stage 2 of this part in March 2021.
About the TACT-002 Trial
TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.The trial is a Phase II, Simon’s two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in study centres across Australia, Europe, the UK and US.
Patients participate in one of the following:
• Part A - First line Non-Small Cell Lung Cancer (NSCLC), PD-X naive
• Part B - Second line NSCLC, PD-X refractory
• Part C - Second line Head and Neck Squamous Cell Carcinoma (HNSCC), PD-X naiveTACTI-002 is an all-comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC. PD-L1 expression is typically reported in three groups for NSCLC: < 1%, 1-49% and ≥ 50% (Tumour Proportion Score or TPS) and in HNSCC: < 1, 1-19 and ≥ 20 (Combined Positive Score or CPS). Patients with a high PD-L1 status are typically more responsive to anti-PD-1 therapy such as pembrolizumab, whereas those with low PD-L1 status are overall significantly less responsive.
More information about the trial can be found on Immutep’s website or on ClinicalTrials.gov (Identifier:
NCT03625323)
- Forums
- ASX - By Stock
- IMM CHART / SP
Immutep LimitedWed, 1 September 2021, 10:00 pmIn this...
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $537.4M |
Open | High | Low | Value | Volume |
36.5¢ | 37.0¢ | 35.5¢ | $459.4K | 1.254M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 63364 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 133642 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 63364 | 0.365 |
3 | 47904 | 0.360 |
5 | 45648 | 0.355 |
10 | 208150 | 0.350 |
4 | 20770 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 133642 | 8 |
0.375 | 64696 | 4 |
0.380 | 99854 | 5 |
0.385 | 101562 | 6 |
0.390 | 197301 | 5 |
Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online